Cullinan Therapeutics (CGEM) Projected to Post Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is expected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.80) per share and revenue of $3.6670 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.03. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

NASDAQ CGEM opened at $14.82 on Wednesday. The stock has a market cap of $910.93 million, a PE ratio of -4.41 and a beta of -0.09. The firm has a 50-day moving average of $14.24 and a 200-day moving average of $11.75. Cullinan Therapeutics has a 52-week low of $5.68 and a 52-week high of $16.74.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Friday, April 10th. Wedbush upped their target price on Cullinan Therapeutics from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday, March 11th. BTIG Research reiterated a “buy” rating and set a $38.00 target price on shares of Cullinan Therapeutics in a research note on Monday. Guggenheim initiated coverage on Cullinan Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $30.00 price target for the company. Finally, Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.89.

Insiders Place Their Bets

In other news, insider Jennifer Michaelson sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.68, for a total transaction of $125,440.00. Following the transaction, the insider directly owned 170,844 shares of the company’s stock, valued at approximately $2,678,833.92. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nadim Ahmed sold 13,515 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $14.47, for a total transaction of $195,562.05. Following the completion of the sale, the chief executive officer owned 390,803 shares of the company’s stock, valued at approximately $5,654,919.41. The trade was a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 78,492 shares of company stock worth $1,113,359. 6.07% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its position in shares of Cullinan Therapeutics by 501.8% during the 3rd quarter. Squarepoint Ops LLC now owns 90,318 shares of the company’s stock valued at $536,000 after acquiring an additional 75,310 shares during the period. Jane Street Group LLC increased its position in shares of Cullinan Therapeutics by 42.1% in the second quarter. Jane Street Group LLC now owns 48,883 shares of the company’s stock worth $368,000 after purchasing an additional 14,487 shares during the period. Two Sigma Investments LP bought a new position in shares of Cullinan Therapeutics in the third quarter worth $354,000. Ameriprise Financial Inc. raised its stake in Cullinan Therapeutics by 25.4% in the third quarter. Ameriprise Financial Inc. now owns 56,777 shares of the company’s stock valued at $337,000 after purchasing an additional 11,485 shares in the last quarter. Finally, Brevan Howard Capital Management LP raised its stake in Cullinan Therapeutics by 138.9% in the third quarter. Brevan Howard Capital Management LP now owns 45,936 shares of the company’s stock valued at $272,000 after purchasing an additional 26,709 shares in the last quarter. Institutional investors own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.